Gilead Sciences (NASDAQ:GILD) Director Sells $2,675,160.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) Director Anthony Welters sold 18,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the sale, the director owned 12,894 shares in the company, valued at approximately $1,916,306.28. This represents a 58.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Trading Down 2.1%

Shares of GILD opened at $145.68 on Friday. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The stock has a market cap of $180.64 billion, a PE ratio of -54.56 and a beta of 0.32. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The stock has a 50 day simple moving average of $134.25 and a 200-day simple moving average of $136.62.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same quarter in the previous year, the firm earned $2.01 EPS. Gilead Sciences’s quarterly revenue was up 10.6% on a year-over-year basis. On average, sell-side analysts predict that Gilead Sciences, Inc. will post -0.5 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s payout ratio is currently -122.85%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The FDA approved Bixlenvo, a once-daily single-tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. It is the first and only single-tablet option for patients on complex regimens who cannot use currently available alternatives, potentially expanding Gilead’s HIV franchise and supporting its longer-term lenacapavir strategy. Reuters FDA approval article
• Positive Sentiment: The European Commission approved Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients, strengthening Gilead’s oncology portfolio and adding a potential growth opportunity outside its core HIV business. EU Trodelvy approval article
• Neutral Sentiment: Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target of approximately $158. However, GILD’s strong multi-year advance may have raised expectations and limited the immediate upside from the Bixlenvo approval. Gilead valuation article
• Negative Sentiment: Director Anthony Welters sold 18,000 shares worth about $2.68 million, reducing his position by roughly 58%. The sale occurred under a pre-arranged Rule 10b5-1 plan, making it a limited bearish signal, but it may still weigh modestly on investor sentiment. SEC insider transaction filing

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on GILD shares. Rothschild & Co Redburn cut their price target on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th. Truist Financial decreased their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a report on Wednesday, May 20th. Finally, Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Twenty-four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.04.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Persistent Asset Partners Ltd acquired a new stake in Gilead Sciences in the second quarter worth about $25,000. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences during the 4th quarter valued at about $25,000. Kimelman & Baird LLC bought a new position in shares of Gilead Sciences in the 2nd quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC grew its position in shares of Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 85 shares during the period. Finally, Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $26,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.